UBS Group’s ProShares Ultra CRCL CRCA Stock Holding History

UBS Group’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-140	Closed	-$5.64K	–	11681
2025 Q4	$5.64K	Buy	+140	New	+$12K	﹤0.01%	8651

Other funds holding CRCA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group's CRCA Position: Q1 2026 in Review

UBS Group sold out of ProShares Ultra CRCL (CRCA) in Q1 2026, closing a stake of 140 shares — an estimated $5.64K sold.

UBS Group first reported a position in CRCA in Q4 2025 and held it in 1 quarter. The position peaked at $5.64K in Q4 2025. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

UBS Group reported no remaining ProShares Ultra CRCL position as of Q1 2026 after selling out during the quarter.
UBS Group sold 140 ProShares Ultra CRCL shares in Q1 2026, an estimated $5.64K.
UBS Group first reported a position in ProShares Ultra CRCL in Q4 2025 and held it in 1 quarter.
UBS Group's ProShares Ultra CRCL position peaked at $5.64K in Q4 2025.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.